The ligand-switchable nanocarriers (LSNs) concealed CPPs into the bloodstream and expose them upon entering into the tumor sites, and overall improving the therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: